Evidence map›Paper›PMID 30908637›Full record

ArticleAlcoholism, clinical and experimental research2019

Hepatic Inactivation of the Type 2 Deiodinase Confers Resistance to Alcoholic Liver Steatosis.

Tatiana L Fonseca, Gustavo W Fernandes, Barbara M L C Bocco, Ali Keshavarzian, Shriram Jakate, Terrence M Donohue, Balázs Gereben, Antonio C Bianco

Open access · greenAbstract read
In one paragraph

Article in Alcoholism, clinical and experimental research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Actions of thyroid hormones and thyromimetics on the liver.Nature reviews. Gastroenterology & hepatology · 2025
    Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Thyroid Hormone and Alcoholic Fatty Liver: The Developmental Input.Alcoholism, clinical and experimental research · 2019
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Tatiana L FonsecaSection of Endocrinology, Diabetes and Metabolism , University of Chicago, Chicago, Illinois.
Gustavo W FernandesSection of Endocrinology, Diabetes and Metabolism , University of Chicago, Chicago, Illinois.
Barbara M L C BoccoSection of Endocrinology, Diabetes and Metabolism , University of Chicago, Chicago, Illinois.
Ali KeshavarzianDivision of Digestive Diseases and Nutrition , Rush University, Chicago, Illinois.
Shriram JakateDepartment of Pathology , Rush University, Chicago, Illinois.
Terrence M DonohueDepartment of Internal Medicine , University of Nebraska Medical Center, Omaha, Nebraska.
Balázs GerebenDepartment of Endocrine Neurobiology , Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest, Hungary.
Antonio C BiancoSection of Endocrinology, Diabetes and Metabolism , University of Chicago, Chicago, Illinois.ORCID 0000-0001-7737-6813
University of Chicago · USRush University · USHUN-REN Institute of Experimental Medicine · HUUniversity of Nebraska Medical Center · US

Funding

SELENODEIODINAS PROCESSING BY THE PROTEASOME SYSTEMR01DK058538 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BIANCO, ANTONIO C, GEREBEN, BALÁZS · 2001 to 2024
$6.0M
Thyroid-adrenergic synergism and adaptive thermogenesisR01DK065055 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BIANCO, ANTONIO C · 2005 to 2021
$4.4M
Selenodeidinase Processing by the Proteasome SystemR56DK058538 · NIDDK · UNIVERSITY OF CHICAGO · PI BIANCO, ANTONIO C · 2019 to 2019
$203k
NIDDK NIH HHS R01 DK058538NIDDK NIH HHS R01 DK065055NIDDK NIH HHS R56 DK058538Wellcome Trust
6 · The paper itself

Abstract

backgroundA mouse with hepatocyte-specific deiodinase type II inactivation (Alb-D2KO) is resistant to diet-induced obesity, hepatic steatosis, and hypertriglyceridemia due to perinatal epigenetic modifications in the liver. This phenotype is linked to low levels of Zfp125, a hepatic transcriptional repressor that promotes liver steatosis by inhibiting genes involved in packaging and secretion of very-low-density lipoprotein.

methodsHere, we used chronic and binge ethanol (EtOH) in mice to cause liver steatosis.

resultsThe EtOH treatment causes a 2.3-fold increase in hepatic triglyceride content; Zfp125 levels were approximately 50% higher in these animals. In contrast, Alb-D2KO mice did not develop EtOH-induced liver steatosis. They also failed to elevate Zfp125 to the same levels, despite being on the EtOH-containing diet for the same period of time. Their phenotype was associated with 1.3- to 2.9-fold up-regulation of hepatic genes involved in lipid transport and export that are normally repressed by Zfp125, that is, Mttp, Abca1, Ldlr, Apoc1, Apoc3, Apoe, Apoh, and Azgp1. Furthermore, genes involved in the EtOH metabolic pathway, that is, Aldh2 and Acss2, were also 1.6- to 3.1-fold up-regulated in Alb-D2KO EtOH mice compared with control animals kept on EtOH.

conclusionsEtOH consumption elevates expression of Zfp125. Alb-D2KO animals, which have lower levels of Zfp125, are much less susceptible to EtOH-induced liver steatosis.

Indexed as

AlcoholismAnimalsBinge DrinkingDietDNA-Binding ProteinsEthanolFatty LiverFatty Liver, AlcoholicGene Expression RegulationIodide PeroxidaseIodothyronine Deiodinase Type IILipid MetabolismLiverMetabolic Networks and PathwaysMiceMice, KnockoutDNA-Binding ProteinsEthanolIodide PeroxidaseIodothyronine Deiodinase Type IITriglyceridesZfp125 protein, mouseDeiodinaseEthanolLipogenesisLiverSteatosisThyroid Hormone

Identifiers

PMID30908637
PMCPMC6602874
OpenAlexW2942172983

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.